Core Viewpoint - Weixin Kang (603676) announced that its wholly-owned subsidiary, Baiyi Pharmaceutical, received a "Notice of Termination of Drug Registration Application" from the National Medical Products Administration, agreeing to withdraw the registration application for the pediatric compound amino acid injection (20AA) [1] Group 1 - The drug in question is an intravenous parenteral nutrition solution intended for nutritional support in children, infants, and newborns [1]